SOPHiA GENETICS (SOPH) Current Deferred Revenue (2020 - 2026)

SOPHiA GENETICS has disclosed Current Deferred Revenue across 7 years of filings, most recently posting $15.6 million for Q2 2026.

• In Q2 2026, Current Deferred Revenue rose 61.84% year-over-year to $15.6 million; the TTM figure through Jun 2026 stood at $15.6 million (up 61.84% YoY), while the FY2025 annual figure was $16.7 million, up 191.7% from the prior year.
• Current Deferred Revenue came in at $15.6 million for Q2 2026 at SOPHiA GENETICS, down from $15.9 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $16.7 million in Q4 2025 to a low of $3.4 million in Q4 2022.
• Average Current Deferred Revenue over 5 years is $8.8 million, with a median of $8.2 million recorded in 2023.
• Year-over-year, Current Deferred Revenue soared 3657.97% in 2022 and tumbled 39.63% in 2024.
• Over 5 years, Current Deferred Revenue stood at $3.4 million in 2022, then surged by 176.47% to $9.5 million in 2023, then plunged by 39.63% to $5.7 million in 2024, then surged by 191.7% to $16.7 million in 2025, then retreated by 6.6% to $15.6 million in 2026.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $15.6 million in Q2 2026, $15.9 million in Q1 2026, and $16.7 million in Q4 2025.